Balyasny Asset Management
BCRX icon

Balyasny Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Balyasny Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-900,000
Closed -$1.8M – 1129
2020
Q1 		$1.8M Buy
+900,000
New +$2.48M 0.02% 634

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Balyasny Asset Management's BCRX Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 186,125 shares worth $1.77M. The stake represents ﹤0.01% of the portfolio and ranks #1840 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in BCRX as recently as Q3 2025.

Balyasny Asset Management first reported a position in BCRX in Q2 2015 and has held it in 13 quarters since. The position peaked at $15.4M in Q3 2022. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Balyasny Asset Management held 186,125 shares of BioCryst Pharmaceuticals worth $1.77M as of Q1 2026.
  • BioCryst Pharmaceuticals was a new Balyasny Asset Management position in Q1 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1840 holding.
  • Balyasny Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2015 and has held it in 13 quarters since.
  • Balyasny Asset Management's BioCryst Pharmaceuticals position peaked at $15.4M in Q3 2022.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.